Tag

Mbp134

All articles tagged with #mbp134

health2 months ago•6 min saved

Experimental Ebola treatment trial begins in Congo, offering cautious hope

A WHO-backed trial in Bunia, Ituri province, Congo, launches to test remdesivir, the MBP134 antibody, or both for Bundibugyo Ebola patients, with 28‑day survival tracking; the first participant is enrolled and the study is expected to last 3–6 months, potentially expanding to high‑risk groups later. The outbreak has diagnosed over 1,400 cases and at least 438 deaths, amid mistrust, overcrowded treatment centers, and security challenges that complicate the response.

via Politico|

#bundibugyo-virus #congo #ebola

health2 months ago•4 min saved

US Expands Ebola Fight by Supplying Experimental Drug for Congo Trials

The U.S. is providing stockpiled doses of Mapp Biopharmaceutical’s experimental MBP134 antibody for compassionate use in the Democratic Republic of Congo and to help run a WHO-coordinated clinical trial, marking the first direct U.S. involvement in testing this therapy as part of broader Ebola response efforts amid the Bundibugyo outbreak; trials of MBP134 and Gilead antivirals are planned in coming weeks.

via NBC News|

#clinical-trials #congo #ebola

health3 months ago•10 min saved

WHO prioritizes Bundibugyo Ebola countermeasures and calls for rapid clinical trials

WHO convened expert groups to evaluate candidate vaccines and therapeutics for Bundibugyo virus disease (BDV) outbreaks in the Democratic Republic of the Congo and Uganda. With no BDV-specific licensed treatments or vaccines, experts prioritized three therapeutics for evaluation in clinical trials—MBP134, Maftivimab, and remdesivir—with combination therapy also considered, and looked at obeldesivir for post‑exposure prophylaxis. The most promising BDV vaccine candidates are a single‑dose rVSV Bundibugyo vaccine (7–9 months to readiness for trials) and ChAdOx1 Bundibugyo (2–3 months to efficacy testing), while Ervebo should not be used outside carefully designed research settings to assess BDV protection. The initiative emphasizes ethics, rapid trial design, accelerated access to supplies, and strengthened outbreak control as trials proceed.

via World Health Organization (WHO)|

#bundibugyo-virus-disease #clinical-trials #ebola-vaccines

health3 months ago•10 min saved

DRC Ebola Outbreak Pushes Bundibugyo-Specific Vaccine and Therapy Efforts

An ongoing Bundibugyo-strain Ebola outbreak in the DRC—the third-largest on record—has no approved strain-specific vaccine or treatment. The existing Zaire-targeted Ervebo vaccine may offer limited cross-protection, but data are scarce and safety in this outbreak is uncertain. New Bundibugyo-focused vaccines (including a vesicular stomatitis virus–based candidate) are in development, though clinical-grade material and human trials likely won’t be ready for six to nine months. Therapies such as remdesivir and the MBP134 monoclonal antibody cocktail show promise, but delivery and safety in the field pose challenges. Beyond vaccines and drugs, rapid diagnosis, isolation, contact tracing, and strong outbreak response remain essential tools for control.

via CNN|

#bundibugyo #ebola #ervebo

health3 months ago•2 min saved

US Enlists San Diego Biotech for Experimental Ebola Antibody Therapy

The U.S. government has tapped San Diego biotech Mapp Biopharmaceutical to supply doses of the experimental Ebola antibody MBP134 for potential use in high-risk individuals amid a Bundibugyo outbreak; MBP134 was developed with BARDA for Sudan virus and has shown preclinical cross-protection against Bundibugyo; use would be coordinated by the FDA and is not yet approved, with supply details not disclosed.

via Fierce Biotech|

#barda #ebola #fda

health3 months ago•6 min saved

Outbreak Sparks Rapid Drug Trials for Ebola Bundibugyo

The Ebola Bundibugyo outbreak in the DRC and Uganda has prompted fast-tracked, WHO-backed clinical trials of two therapies—MBP134 antibodies and remdesivir—with government approvals pending; MBP134 shows strong animal data and remdesivir has prior antiviral use, as researchers aim to quickly assess effectiveness against this Ebola species amid thousands of suspected cases and deaths.

via Nature|

#bundibugyo-virus #ebola #health